Anti-Human CD194 Recombinant Antibody

Name: Anti-Human CD194 Recombinant Antibody
Brand: KMD Bioscience
SKU: YR1245

YR1245

科研级 Mogamulizumab ( 莫格利组单抗 ), Anti-CD194 Recombinant Antibody, Research Grade Mogamulizumab

DATASHEET MSDS

Product Description

Alias	科研级 Mogamulizumab ( 莫格利组单抗 ), Anti-CD194 Recombinant Antibody, Research Grade Mogamulizumab
Catalog Number	YR1245
Molecular Name	Mogamulizumab
Size	1mg, 5mg
Clonity	Monoclonal
Purity	>95% as determined by SDS-PAGE
Concentration	1mg/ml
Antibody Isotype	IgG1 Kappa
Formulation	PBS, pH7.5
Background	Mogamulizumab, sold under the brand name Poteligeo, is a humanized, afucosylated monoclonal antibody targeting CC chemokine receptor 4 (CCR4). The U.S. Food and Drug Administration (FDA) approved it in August 2018 for treatment of relapsed or refractory mycosis fungoides and Sézary disease. It was approved in Japan in 2012, for the treatment of relapsed or refractory CCR4+ adult T-cell leukemia/lymphoma (ATCLL) and in 2014, for relapsed or refractory CCR4+ cutaneous T cell lymphoma (CTCL).
CAS Number	1159266-37-1
Storage Condition	It is recommended to aliquote and store at -20°C for long term storage. Avoid repeated freezing and thawing cycles.
Remarks	This product is for research use only.
Shipping Condition	Shipped on ice packs.
Target	CD194[Homo sapiens]

Login